Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas

Head and neck squamous cell carcinoma (HNSCC) is the 6th most frequently arising tumor worldwide. According to recent estimates from the GLOBOCAN project 2012 the incidence of head and neck cancer (HNC) was >500000 cases per year worldwide. More than 350000 deaths are attributable to HNSCC annually [1]. While local and locoregionally-advanced HNSCC can be treated effectively with surgery, radiation, or chemoradiotherapy, recurrent/metastatic disease prognosis remains poor and both chemotherapy and targeted therapy with the anti-EGFR antibody cetuximab are poorly effective.

from #ORL via xlomafota13 on Inoreader http://ift.tt/1Utt3KM
via IFTTT